Fabrizio Papa Email & Phone Number

North Chicago, Illinois, Us

ImmunoGen is now part of AbbVie.Lead the creation and execution of a long-term brand vision and strategy throughout the European Union and the United Kingdom for ImmunoGen Antibody-Drug Conjugates (ADCs) portfolio.

Zug, Ch

Re-focused the Acne global organisation and defined insights-driven priorities and strategies to bring back the franchise to the #1 position globally. Built a new global acne commercial team that shared a strong performance culture and aimed to achieve outstanding results. Led the Global Product Team (GPT) to find new opportunities for growth and enhance the global performance of the franchise, organically and also via new product acquisitions and launches. Shared Acne P&L responsibility with the four regions.▶︎ Defined the strategy and launched Twyneo®, the first ever combination of tretinoin and BPO, in US.▶︎ Created the first Galderma Acne Franchise co-positioning, leveraging the data from extensive research including HCPs, patients and consumers. Portfolio includes 7 products: Twyneo®, Aklief®, Epiduo®, Epiduo Forte®, Differin®, Benzac®, and Tetralysal®.▶︎ Re-positioned and defined the priorities to expand the Aklief® brand geographically so that it could reach double the number of countries by end of 2025 and become the #1 topical retinoid globally.

Tokyo, Jp

Devised and implemented global marketing strategy for Takeda's rare diseases franchise to ensure maximum business and revenue growth. Led and inspired global branding team to improve overall performance. Led and directed cross-functional project team spanning global, regional, and country levels to ensure business strategies, aligned and implemented consistently. Interacted and liaised with business development teams to uncover and develop business case for additional opportunities to grow global franchise. ▶︎ Created a new positioning, vision, and strategy for the whole haemophilia portfolio, co-positioning the various products to address different patient profiles, focusing on value for patients. Portfolio includes 3 products: ADYNOVATE®, ADVATE®, and OBIZUR®.▶︎ Granted full label to critical brand ADYNOVATE® in Brazil▶︎ Drove full strategy process from start to end in co-creation with regions and countries who then more easily adopted and localised it.

Stockholm, Stockholm County, Se

Steered affiliate haemophilia launch strategies implementation and global-local coordination as leader of Haemophilia Business Unit Directors Board. Member of HQ Core strategic planning team overseeing Sobi's new and first-in-class Extended Half Life haemophilia drugs (Elocta® and Alprolix®). Ensured maximum brand development to boost highest profit generation by formulating and executing effective marketing strategies.▶︎ Established new process to track and evaluate the launch of two new products in all countries.▶︎ Spearheaded new key account management global project, with a tailored approach to prioritised accounts from a truly cross-functional perspective - ONE team, commercial, medical and access.

Bagsværd, Dk

During this tenure, I strategically administered Novo Nordisk Insulin portfolio across vast region, South and Central America, Middle East, Africa, Asia-Pacific. Organised and oversaw diabetes marketing board of directors. Represented and organised broad and coordinated area voice in CCTs (strategic forums) and deliver consistent regional business perspectives and requirements. Acted as member of Global Insulin Life Cycle Management. Led European launch of new recombinant Factor VIII. First point of entry to ensure effective Global-Regional-Local commercial cooperation with European Board of Sales and Marketing Directors of Biopharm Unit (Haemophilia, Rare Endocrine, and Hormone Replacement Therapy).▶︎ Established first cross-country experience exchange and best practice sharing annual event as a regional marketing manager.▶︎ Increased 40% patients market share of a key product for the company, NovoSeven® by steering Pan-European project▶︎ Drove new targeting and segmentation approach that allowed to redefine the customer base, focusing on the highest potential ones within the Diabetes unit.

Bagsværd, Dk

Led Novo Nordisk's rare diseases portfolio sales in Italy. Managed national sales KAM team within rare diseases area. Led marketing team.▶︎ Achieved market leadership in only six months by re-focusing whole sales organisation and identifying right competitor to target.▶︎ Devised new strategy to maximise opportunity for company portfolio based on a vast disease awareness campaign that brought to an increment of 50% in diagnosis rate and 30% patients market share increase.Additional experience as Sales Representative at MSD, Daiichi Sankyo, Menarini

Master Of Science In Biology, Biology/Biological Sciences, General

Marketing Strategies